ALSO IN THIS MONTH'S ISSUE
Against All Odds: Advancing From R&D To Phase 3
There is nothing more rewarding than knowing that we can help save a life and give hope to patients and their friends and families. Because lives are at stake, there must be more regulations and processes to ensure safety and efficacy.
Coming Out Of Stealth Mode: What To Know And Do
Five CEOs discuss their experiences with stealth mode transitions. They address when and how a company should turn away from that introspective state and show itself to the world.
The Collective Benefits Of A Collaborative CFO
Terry Coelho, CFO, works as a team member, not just a finance manager, at BioDelivery Sciences.
From Fusion Energy To Med Device … To Drug Developer?
TAE Life Sciences wanted to create a combination product that brought together its neutron beam with a drug that delivers boron to cancer cells. But, the company didn’t want to be in a position where it relied on another company for the drug needed.
BEYOND THE PRINTED PAGE
Did You Expect It Would Take This Long To Go Public?7/19/2021
Laura Niklason, M.D., Ph.D., cofounder and CEO of Humacyte, explains some of the science of her regenerative medicines company so to be public via a SPAC.
Have You Heard Of Eric Dube?6/17/2021
A primer on what makes Eric Dube, Ph.D., CEO of Travere Therapeutics and upcoming feature in Life Science Leader, so inspirational.
How We Have Changed For The Better Thanks To COVID-195/17/2021
An interview with Mei Mei Hu, cofounder and CEO of Vaxxinity, provides an example of how COVID-19 and Zoom have enabled the seeing and showing of one another’s humanness.